Cargando…

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Gay, F, Berdeja, JG, De Stefano, V, Hari, P, Hooper, B, Haltner, A, Kumar, S, Martin, T, Mateos, M-V, Moreau, P, Rosta, E, Samjoo, IA, Usmani, SZ, Weisel, K, Jackson, CC, Olyslager, Y, Schecter, JM, Vogel, M, Garrett, A, Lee, S, Nesheiwat, T, Pacaud, L, Zhou, C, Valluri, S, Costa, LJ, Lin, Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Best Abstracts - Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009793/ http://dx.doi.org/10.1097/01.HS9.0000829560.21894.ee

Ejemplares similares

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
por: van de Donk, NWCJ, et al.
Publicado: (2022)

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2021)

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
por: Weisel, Katja, et al.
Publicado: (2021)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
por: Weisel, K., et al.
Publicado: (2022)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
por: Hillengass, J., et al.
Publicado: (2022)

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
por: Martin, Thomas, et al.
Publicado: (2023)

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
por: Einsele, H, et al.
Publicado: (2022)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
por: Lin, Y., et al.
Publicado: (2022)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
por: Wu, Liviawati S., et al.
Publicado: (2022)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT
por: Decaux, O., et al.
Publicado: (2022)

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Broijl, A., et al.
Publicado: (2023)

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
por: Delforge, Michel, et al.
Publicado: (2022)

B01 Virtual reality as a teaching method for resuscitation training in undergraduate first year medical students during COVID-19 pandemic: A randomised controlled trial
por: Moll-Khosrawi, Parisa, et al.
Publicado: (2022)

Development and Implementation of the How to Talk to Your Doctor HANDbook Health Literacy Program in Rural Counties
por: Washburn, Lisa, et al.
Publicado: (2019)

Lessons Learned from Using Global Outcome Measures to Assess Community Pharmacy Performance
por: Urick, Benjamin Y., et al.
Publicado: (2018)

B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM
por: Hofste op Bruinink, D., et al.
Publicado: (2023)

How Can Doctors Help Their Patients to Return to Work?
por: Verbeek, Jos H
Publicado: (2006)

Statins in Patients with Chronic Kidney Disease: Evidence from Systematic Reviews and Randomized Clinical Trials
por: Navaneethan, Sankar D, et al.
Publicado: (2006)

Vitamin C for Preventing and Treating the Common Cold
por: Douglas, Robert M, et al.
Publicado: (2005)

Educating the Brain to Avoid Dementia: Can Mental Exercise Prevent Alzheimer Disease?
por: Gatz, Margaret
Publicado: (2005)

Antidepressant Prevention of Postnatal Depression
por: Howard, Louise M, et al.
Publicado: (2006)

Guidance for laboratories performing molecular pathology for cancer patients
por: Cree, Ian A, et al.
Publicado: (2014)

Fifteen minute consultation: Managing neonatal and childhood herpes encephalitis
por: Le Doare, K, et al.
Publicado: (2015)

Updated UK Recommendations for HER2 assessment in breast cancer
por: Rakha, Emad A, et al.
Publicado: (2015)

On the same page: Co-designing the logic model of a telehealth service for children in rural and remote Australia
por: Abimbola, Seye, et al.
Publicado: (2019)

Applying an affordances approach and a developmental lens to approach adolescent social media use
por: Moreno, Megan A, et al.
Publicado: (2019)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Assessing the Print Communication and Technology Attributes of an Academic Medical Center
por: Leonard, Kelsey, et al.
Publicado: (2018)

Lean Six Sigma Methodology in the Implementation of a Standardized Health Literacy Assessment in a Safety Net Internal Medicine Residency Clinic
por: Penix, Rose, et al.
Publicado: (2019)

Adult Basic Education: Community Health Partnerships and Health Disparities
por: Hohn, Marcia Drew, et al.
Publicado: (2019)

Best Practices to Advance Health Literacy in a Wisconsin Adult Literacy Coalition
por: Erikson, Michele, et al.
Publicado: (2019)

Community Health Literacy Assessment: A Systematic Framework to Assess Activities, Gaps, Assets, and Opportunities for Health Literacy Improvement
por: Platter, Heather, et al.
Publicado: (2019)

“Health in the English Language”: A Partnership With the Alaska Literacy Program
por: Sarkar, Jinia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0e780mqkr7jgk121jvcakvs72n